安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Encoded Therapeutics – Translating Next-Generation Science into . . .
Translating Next-Generation Science Into Transformative Gene TherapiesLearn About Our Programs
- About – Encoded Therapeutics
Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients Our diversity – whether gender, ethnicity, sexual orientation, religion, age or disability – is one of our biggest strengths as an organization
- News – Encoded Therapeutics
October 09, 2025 New Preclinical Data from Encoded Therapeutics Demonstrate Therapeutic Potential of its One-time, Non-opioid Gene Therapy Candidate for Chronic Pain September 02, 2025 Encoded Therapeutics Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U S FDA for ETX101 in SCN1A+ Dravet Syndrome May 13, 2025
- Programs – Encoded Therapeutics
Programs Encoded is building an internally developed pipeline of best- and potentially first-in-class therapies focused on central nervous system (CNS) disorders
- Careers – Encoded Therapeutics
Encoded offers competitive pay, an equity program and benefits We provide the support that team members need at work to succeed, and we give back the benefits and perks to maintain their health and enjoy life outside of the office
- Our Science – Encoded Therapeutics
Ever wondered what it takes to make a gene therapy? Join us on a virtual lab tour at Encoded’s headquarters in South San Francisco Meet a few of our talented scientists ready to explain what goes on behind the scenes as we work to develop potential, transformative therapies
- Clinical Studies – Encoded Therapeutics
Encoded carefully designs clinical studies to assess safety and efficacy of its investigational gene therapies for the treatment of pediatric CNS disorders People considering enrolling their child in an Encoded study should evaluate eligibility by speaking with their child’s physician
- ETX101 for Dravet Syndrome – Encoded Therapeutics
Encoded is developing ETX101, a potential one-time, disease-modifying gene regulation therapy for SCN1A+ Dravet syndrome ETX101, Encoded’s lead program, is specifically designed to address the underlying cause of Dravet syndrome, the most common developmental and epileptic encephalopathy
|
|
|